SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently trading in a tight consolidation range as investors weigh record-breaking revenue and strong AI infrastructure demand against margin compression concerns and lingering sentiment around historical accounting reports. The community is actively debating the company's long-term value, with many hopeful that upcoming industry conferences and strategic NVIDIA ecosystem partnerships will finally catalyze a breakout from the stock's multi-month sideways trend.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple's XRP is trending as traders closely monitor its recent price action and resistance levels, with many community members debating whether the current move is a sustainable breakout or another manipulation trap. The conversation is heavily polarized between long-term holders citing institutional adoption and potential utility, and skeptics who remain wary of market volatility and its historical correlation with broader crypto movements.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging following a massive five-year, $27 billion AI infrastructure deal with Meta, which builds on a recent $2 billion equity investment from Nvidia. The community is heavily focused on the company's rapid hyperscaler expansion, debating the implications of this contract for future revenue and whether the stock's valuation is poised for a sustained breakout or a potential pullback.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is gaining traction as investors focus on its proprietary real-time 3D sonar technology, which is increasingly critical for subsea infrastructure, defense, and maritime security. The community is actively discussing the stock's multi-bagger potential, high institutional interest, and the significant demand for its specialized equipment in global underwater operations.

Citi Trends, Inc. engages in the retail of urban fashion apparel, accessories, and home trends. It offers products under its Citi Steps and Red Ape brands. The company was founded in 1946 and is headquartered in Savannah, GA.

Citi Trends Inc

Citi Trends is currently trending as investors monitor its strategic turnaround plan, which includes store expansion and inventory management, alongside a raised fiscal outlook that has drawn significant attention from traders. The community is actively debating the company's long-term operational consistency and its ability to navigate current consumer spending headwinds.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant investor attention due to a surge in trading volume and speculation regarding a potential short squeeze, fueled by its pivot toward stablecoin settlement and institutional infrastructure. The community is actively discussing recent corporate developments, including share dilution, and is keenly anticipating an upcoming Investor Day that many hope will clarify the company's long-term growth strategy.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing significant operational headwinds as a prolonged government shutdown triggers mandatory flight capacity cuts and widespread cancellations, putting pressure on industry profit guidance. Despite these challenges, market sentiment remains cautiously optimistic as investors monitor the impact of rising fuel costs against the backdrop of robust travel demand and resilient corporate booking trends.

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals is capturing investor attention following consistently positive clinical data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis, which validates the potential of its DiffuSphere delivery technology. The community is actively discussing the company's progress toward Phase 2b development and its growing pipeline, while analysts remain focused on the stock's long-term commercial potential and upcoming milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a report, AIG’s competitor, Chubb, approached the firm with an informal offer to acquire it; however, both Chubb and AIG denied the reports.</li><li>Citi maintained its ‘Neutral’ rating on AIG and assigned an $85 price target.</li><li>Piper Sandler raised its price target on the stock to $95 from $88 and maintained an ‘Overweight’ rating.</li></ul>American International Group (<a href="https://stocktwits.com/symbol/AIG">AIG</a>) stock drew investor attention on Monday after Citi analysts noted that merging with another large insurer would not benefit AIG.According to TheFly, Citi analysts wrote in a research note that they expect American International Group (AIG) to continue acquiring more firms rather than being acquired. Citi believes integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction. The firm maintained a ‘Neutral’ rating on the shares, with an $85 price target.Earlier in the month, an Insurance Insider US <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insuranceinsiderus.com/article/2fpahsm5la3on7eapsfsw/all-topics/m-a/chubb-made-informal-takeover-approach-for-aig?zephr_sso_ott=LTYHsi">report</a> indicated that Chubb had approached AIG with an informal acquisition offer. However, both firms have reportedly <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insurancenews.com.au/international/aig-not-for-sale-amid-reports-of-rival-s-interest">denied</a> the same, according to Insurance News.&nbsp;In another note, Piper Sandler raised its price target on AIG to $95 from $88 and maintained an Overweight rating. The firm expects favorable weather to mean most insurers will report strong or even stronger-than-expected results, but pricing commentary will likely be more pessimistic.<h2 class="st-heading-2">Expansion Amidst Streamlining Operations</h2>AIG’s CEO, Peter Zaffino, has been streamlining its operations since taking the reins in 2021 by selling its global personal travel business, and continues to make acquisitions and investments to make AIG into a more capital-aligned company.AIG recently announced it will invest around $5 billion in specialty insurer Convex and asset manager Onex Corporation. As part of the deal, AIG acquired a 35% stake in Convex for $2.1 billion. It also said it will acquire a 9.9% ownership stake in asset manager Onex for about $646 million and will also invest up to $2 billion in its investment funds.AIG also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.everestglobal.com/news/news-details/2025/Everest-Announces-Agreement-to-Sell-Retail-Commercial-Insurance-Renewal-Rights-to-AIG/default.aspx">acquired</a> renewal rights to Everest Group’s global retail insurance portfolio for about $2 billion, which will allow AIG to grow its general insurance arm by incorporating Everest’s existing customers.<h2 class="st-heading-2">How Did Stoctwits Users React?</h2>Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes.<figure class="image"><img style="aspect-ratio:633/74;" src="https://news.stocktwits-cdn.com/AIG_PNG_22be5e3e02.webp" alt="Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes" width="633" height="74"></figure>Shares of AIG have surged over 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The AIG (American International Group) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Does Citi Believe AIG Is More Likely To ‘Acquire’ Than Be Acquired?

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.

Equity

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.


Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nalu-medical-inc-302587495.html">expected</a> to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BSX">BSX stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said."Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.BSX stock is up by 9% this year and by about 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-105-000-pulling-mstr-stock-lower-xrp-and-solana-drop/ch6sexmR383">Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Nalu Medical is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

Three varieties of McCormick spices in plastic table shaker containers. Salt free all purpose, garlic and herb and Perfect Pinch salt free garlic and herb. Variety of prepared and mixed Seasonings to add to any food dish.

McCormick CEO Flags Rising Prices On Global Trade Pressures: ‘Expect To Offset Rising Commodity Costs And Tariffs As Much As We Can’

McCormick now expects annual adjusted profit to be between $3 and $3.05 per share, compared with its previous estimate of $3.03 to $3.08 per share.

Med-tech company Medtronic (MDT) announced on Tuesday that its board of directors has appointed industry veterans John Groetelaars and Bill Jellison as independent directors, effective immediately, after Elliott Investment Management added a substantial stake in the firm.The company also announced the formation of two special committees. Of this, one will be responsible for guiding the evaluation and execution of growth-accretive tuck-in mergers and acquisitions, organic research and development investments, and potential divestitures.The other committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, the company said.CEO Geoff Martha will serve as Chair of both of the newly formed committees, and both the newly appointed directors will serve on one or both of the committees. Groetelaars and Jellison will further be nominated to stand for election to the board at Medtronic's 2025 annual general meeting of shareholders, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-announces-Board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities">said</a>.The company said that the move followed dialogue with Elliott Investment Management L.P., which is now one of the largest investors in the company. Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation.“We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth… Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential,” Steinberg said.The Wall Street Journal reported the board appointments earlier today. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MDT">MDT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_7_52_05_AM_png_5d5cc8d38a.webp" alt="MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company’s long-term value looks solid, if it can maintain steady revenue growth and keep innovating in key product lines.<stembedurl>https://stocktwits.com/JasonInsightMarkets/message/625725317</stembedurl>On Tuesday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results">reported</a> earnings for the first quarter of fiscal year 2026 (FY26), which ended July 25, and raised its FY26 earnings guidance. For FY26, the company continues to expect organic revenue growth of approximately 5%. It also raised its FY26 diluted and adjusted earnings per share guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60.For the first quarter, the firm reported revenue of $8.578 billion, exceeding a Wall Street estimate of $8.371 billion. The growth was spurred by growth across the company’s cardiovascular, neuroscience, medical surgical, and diabetes business portfolios.Adjusted and diluted earnings per share in the quarter came in at $1.26, above an estimated $1.23.MDT stock is up by 16% this year and by about 9% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-readying-new-blackwell-based-b30-a-chip-for-china-as-us-tensions-flare-report/chsgO5iRdg9">Nvidia Readying New Blackwell-Based B30A Chip For China As US Tensions Flare: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Medtronic logo is displayed on a smartphone screen in front of a stock chart showcasing Medtronic's financial performance. (Photo by Cheng Xin/Getty Images)

Medtronic Appoints New Directors After Elliott Becomes Major Investor: Company Hikes FY26 Guidance After Q1 Beat

Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation. 

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover renal denervation for uncontrolled hypertension.CMS on Thursday posted its proposed decision memo, stating that it proposes to cover radiofrequency renal denervation and ultrasound renal denervation for uncontrolled hypertension. The agency is now seeking comments on its proposed decision, and a final decision is expected by October 8.Renal denervation (RDN) is a new technology that uses catheters placed into the renal (kidney) arteries to ablate, or destroy, the renal sympathetic nerves to reduce blood pressure. RDN is intended to complement medications and lifestyle changes in patients with uncontrolled hypertension.Hypertension can lead to serious problems such as heart attack and stroke, the agency noted.Medtronic, the medical technology provider, has an RDN system called Symplicity Spyral, which was granted FDA premarket approval in November 2023. The system disrupts the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.<a href="https://stocktwits.com/symbol/MDT">MDT shares </a>were trading 1% higher at the time of writing.&nbsp;Several analysts reacted to the news:<ul style="list-style-type:square;"><li>Stifel maintains a ‘Hold’ rating and $87 price target on Medtronic shares. The Centers for Medicare &amp; Medicaid Services' initial proposal for renal denervation reimbursement "seems positive," the firm noted.</li><li>JPMorgan, meanwhile, keeps a ‘Neutral’ rating on Medtronic. JPMorgan told investors in a research note that there is no arguing that a broad national coverage decision for renal denervation is a win for Medtronic. This will enable the company to begin targeting the potentially multi-billion-dollar opportunity once the final rule is released in October, according to the analyst. However, JPMorgan believes it will "take some time to get there" as the company will need to educate primary care physicians and general cardiologists.</li><li>BTIG analyst Ryan Zimmerman keeps a ‘Neutral’ rating on Medtronic. BTIG said that while the news was expected, it is still a win for Medtronic. BTIG believes the decision opens up Medtronic to a "massive" potential patient pool.</li></ul>&nbsp;On Stocktwits, retail sentiment around Medtronic stayed within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_1_28_21_PM_png_9314bf702a.webp" alt="MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by nearly 13% this year and by over 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/cel-sci-to-sign-partnership-with-saudi-arabian-pharma-company-for-cancer-drug/ch8c1PLR5ZC">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts

CMS is now seeking comments on its proposed decision, and a final decision is expected by October 8.

Health technology company Medtronic plc (MDT) on Tuesday announced the appointment of Chad Spooner as CFO of MiniMed.The appointment comes ahead of MiniMed’s separation from Medtronic as a standalone, public company. MDT shares are trading 1% higher at the time of writing.Medtronic announced its <a href="https://stocktwits.com/news-articles/markets/equity/medtronic-announes-split-of-diabetes-business/ch0ec0dRbYg">intent to split</a> its Diabetes business into a standalone company in May. The move, it said, will create a more focused Medtronic, with a more simplified portfolio including cardiovascular, neuroscience, and medical-surgical.The company also noted that the separation is expected to be accretive to Medtronic’s earnings and operating margin.<a href="https://stocktwits.com/symbol/MDT">Medtronic</a> expects the separation to be completed within 18 months of the initial announcement. The company is eyeing an initial public offering (IPO) and subsequent split-off.Que Dallara will be the CEO of the new diabetes company, named MiniMed, which is expected to have over 8,000 employees. Dallara is currently the President of Medtronic Diabetes.Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.He was most recently CFO at BIC, a publicly traded global consumer goods company. Dallara also held leadership roles across healthcare, consumer, and industrial sectors, including at Raffaela Apparel Group, Slingshot Health, and Tenex Capital Management.Medtronic’s diabetes portfolio reported revenue of $2.76 billion in fiscal year 2025 (FY25), marking a growth of 10.7% year-on-year (YoY) and representing 8% of Medtronic’s total revenue in the period.On Stocktwits, retail sentiment around Medtronic is trending in the ‘neutral’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1378/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_12_41_52_PM_png_5beb980fab.webp" alt="MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits" width="1378" height="122"><figcaption>MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by 11% this year and by about 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-seeks-approval-for-higher-wegovy-dose-in-europe/chFvDEAR5Wj">Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medtronic Names CFO For New Diabetes Company Ahead Of Intended Spin-Off

Chad Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.

XRLV
Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XRLV News

XRLVInvesco S&P 500 ex-Rate Sensitive Low Volatility ETF